{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:27Z","timestamp":1781179107988,"version":"3.54.1"},"reference-count":12,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapsed refractory leukemia represents a difficult-to-treat population of patients. The balance between perceived benefit and potential side effects along with the significant financial burden of managing multidrug-resistant sepsis are factors that determine the choice of salvage regimen. Here, we present our experience with the combination of fludarabine, cytarabine, granulocyte-colony stimulating factor with bortezomib. The morphological complete response rate was 58% with 50% of the patients achieving complete remission. With only three patients requiring intensive care unit admission during remission induction, 66.6% of the patients went on to undergo successful hematopoietic stem cell transplantation. Thus, it proved to be a possible, safer alternative to other salvage regimens, while enabling a significant percentage of patients to achieve remission and proceed to allogenic stem cell transplantation.<\/jats:p>","DOI":"10.1055\/s-0044-1785695","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T19:13:12Z","timestamp":1712862792000},"page":"540-543","source":"Crossref","is-referenced-by-count":1,"title":["FLAG with Bortezomib Salvage Therapy in Relapsed\/Refractory Childhood Leukemia\u2014A Reliable Bridge to Transplantation with Limited Toxicity"],"prefix":"10.25259","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-1198","authenticated-orcid":false,"given":"Sreedhar Jayakrishnan","family":"Cherulil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9951-4711","authenticated-orcid":false,"given":"Kesavan","family":"Melarcode Ramanan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Hemato-Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KV","family":"Gangadharan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KP","family":"Sreelesh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5373-0558","authenticated-orcid":false,"given":"Arun","family":"Chandrashekaran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Vaniyath","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hemato-Oncology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthika","family":"KV","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aster Malabar Institute of Medical Sciences, Kozhikode, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1097\/MPH.0000000000001644","article-title":"FLAG with bortezomib in childhood relapsed\/refractory leukemia: remission induction with limited toxicity in the era of multidrug-resistant bacteria","volume":"43","author":"N Ravichandran","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"A E Hoffman","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"ref3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"S P Hunger","year":"2020","journal-title":"Blood"},{"issue":"27","key":"ref4","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"A K Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.1998.00836.x","article-title":"IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial","volume":"102","author":"G Fleischhack","year":"1998","journal-title":"Br J Haematol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"V Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref7","first-page":"1823","article-title":"The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia","volume":"25","author":"I Hubeek","year":"2004","journal-title":"Int J Oncol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"T M Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"e0163090","DOI":"10.1371\/journal.pone.0163090","article-title":"Determinants of treatment abandonment in childhood cancer: results from a global survey","volume":"11","author":"P Friedrich","year":"2016","journal-title":"PLoS One"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Y Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.14505","article-title":"The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood","volume":"176","author":"A Bertaina","year":"2017","journal-title":"Br J Haematol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjh.16005","article-title":"Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India","volume":"186","author":"P Roy","year":"2019","journal-title":"Br J Haematol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1785695.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:12Z","timestamp":1781176392000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/flag-with-bortezomib-salvage-therapy-in-relapsed-refractory-childhood-leukemia-a-reliable-bridge-to-transplantation-with-limited-toxicity\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":12,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1785695","archive":["Portico","CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.171186941.18868408\/v1","asserted-by":"object"}]},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}